Another phase 2 trial (HUDSON) suggested durvalumab plus ceralasertib (an ATR inhibitor) might be an effective treatment option for patients with NSCLC who failed from chemotherapy and anti–PD–L1 therapy (73). This evidence concerns the gene CD274 and non-small cell lung carcinoma.